Alzheimer’s and Covid-19 developers make hay on the stock markets
Big risers include Eli Lilly, Biogen, Moderna and Biontech.
Smaller medtechs suffer, but not from Covid-19
Emergence from lockdown is the driving force behind many – but not all – of the small and mid-cap share price moves.
Role reversal for large-cap medtechs
Shareholders are rewarding the kinds of companies they punished a year ago.
2020 wins top of the froths for biotech stocks
It's official: dramatic share price jumps in response to clinical data have become more common.
